Entrada Therapeutics (TRDA) EBT Margin (2023 - 2025)
Historic EBT Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2693.93%.
- Entrada Therapeutics' EBT Margin fell 26127200.0% to 2693.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 169.83%, marking a year-over-year decrease of 2053500.0%. This contributed to the annual value of 31.55% for FY2024, which is 221700.0% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' EBT Margin is 2693.93%, which was down 26127200.0% from 2201.28% recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' EBT Margin registered a high of 61.03% during Q2 2024, and its lowest value of 2693.93% during Q3 2025.
- Moreover, its 3-year median value for EBT Margin was 12.36% (2023), whereas its average is 452.21%.
- In the last 5 years, Entrada Therapeutics' EBT Margin soared by 1275200bps in 2024 and then plummeted by -26127200bps in 2025.
- Over the past 3 years, Entrada Therapeutics' EBT Margin (Quarter) stood at 22.08% in 2023, then crashed by -109bps to 1.94% in 2024, then tumbled by -139054bps to 2693.93% in 2025.
- Its last three reported values are 2693.93% in Q3 2025, 2201.28% for Q2 2025, and 84.39% during Q1 2025.